Previous close | 259.95 |
Open | 293.00 |
Bid | 287.20 x 30000 |
Ask | 288.55 x 30000 |
Day's range | 287.00 - 295.00 |
52-week range | 199.20 - 304.00 |
Volume | |
Avg. volume | 261 |
Market cap | 155.632B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 22.32 |
EPS (TTM) | 12.86 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | 8.29 (3.19%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insightful Analysis of Amgen Inc's Strengths, Weaknesses, Opportunities, and Threats
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.